Zeria Pharmaceutical clinical trials
The registry lists 33 studies whose lead sponsor is Zeria Pharmaceutical or the company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 24, 2026.
Our grouping of 2 registry names, not the registry’s. See them and correct one ↓
- 33studies on the registry
- 0open to participants now
What it is testing
The drugs Zeria Pharmaceutical’s studies test, most studies first; none is open now — 10 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- Z 3383 in phase 30 open · 7
- Mesalamine3 in phase 30 open · 6
- specific substance maruyama2 in phase 30 open · 3
- Z-2132 in phase 30 open · 3
- 0 open · 3
- 0 open · 2
- omega-3 carboxylic acid2 in phase 30 open · 2
- 0 open · 1
- 0 open · 1
- 0 open · 1
All 33 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 09
- 10
- 11
- 12
- 13
- 414
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 6 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Zeria Pharmaceutical.
- Zeria Pharmaceutical23 studiesSame company
Something wrong?
- Tillotts Pharma AG10 studies →Acquired — became part of Zeria Pharmaceutical, Sep 2009 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 33 of 33.
- A Phase III Trial of Z-338 in Paediatric Patients With Functional DyspepsiaCompletedNCT04526119Phase 3
- A Comparative Study of ZG-801 and Placebo in Patients With HyperkalemiaCompletedNCT04955678Phase 3
- Trial to Optimally Show the Pharmacological Action of Z-100CompletedNCT03476018Phase 3
- Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical CancerCompletedNCT02247232Phase 3
- Exploratory Study of ZG-801 for the Treatment of HyperkalemiaCompletedNCT03799926Phase 2
- TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)CompletedNCT01903252Phase 3
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- Efficacy Study of Intravenous Iron Preparation to Iron Deficiency AnemiaCompletedNCT02731534Phase 3
- Clinical Study of Z-213 in Subjects With Iron-deficiency AnemiaCompletedNCT02828319Phase 3
- Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative ColitisCompletedNCT01059344Phase 3
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- Z-360 Plus GEM in Subjects With Metastatic Pancreatic AdenocarcinomaCompletedNCT02117258Phase 2
- To Evaluate Efficacy and Safety of Z-215 in Erosive EsophagitisCompletedNCT02463643Phase 2
- Phase III, Long-term, Open-label Safety Study of Z-338CompletedNCT01973790Phase 3
- Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate CapsulesCompletedNCT02911298Phase 1
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- Mass Balance and Metabolism Study of 14C-Z-215CompletedNCT02618629Phase 1
- To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male SubjectsCompletedNCT02509923Phase 1
- To Evaluate the Efficacy and Safety in Subjects With Functional DyspepsiaCompletedNCT00323817Phase 2
- Pharmacokinetics, Pharmacodynamics and Safety Study of Z-213 to Iron Deficiency AnemiaCompletedNCT02170311Phase 1
- TP0502-B-Pharmaco-Scintigraphic-StudyCompletedNCT02306798Phase 1
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- TP0501 - Pharmaco-Scintigraphic-StudyCompletedNCT02306772Phase 1
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- TP0502-Pharmaco-Scintigraphic-Study and AmendmentCompletedNCT02306785Phase 1
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- A Healthy Subject Study With Z-360 and PlaceboCompletedNCT01776463Phase 1
- Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic RicketsCompletedNCT01237288Phase 3
- Comparative Efficacy and Safety Study in Patients With Active Ulcerative ColitisCompletedNCT01257386Phase 3
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission PhaseCompletedNCT01257399Phase 3
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- EPANOVA in Crohn's Disease, Study 1CompletedNCT00613197Phase 3
Sponsor listed in the registry: Tillotts Pharma AG · First submitted before Tillotts Pharma AG became part of Zeria Pharmaceutical
- Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00731445Phase 1/2
- To Verify the Efficacy of Z-338 in Subjects With Functional DyspepsiaCompletedNCT00761358Phase 3
- The Effect of Z-338 in Subjects With Functional DyspepsiaCompletedNCT00458328Phase 2
- Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine TreatmentCompletedNCT00288925Phase 1/2
- The Effects of Z-338 in Subjects With and Without Functional DyspepsiaCompletedNCT00298194Phase 2
- To Evaluate the Efficacy of Z-338 in Subjects With Functional DyspepsiaCompletedNCT00333372Phase 2
- An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's DiseaseCompletedNCT00074542Phase 3
Sponsor listed in the registry: Tillotts Pharma AG · First submitted before Tillotts Pharma AG became part of Zeria Pharmaceutical
- Safety and Tolerability of Z-100 in Patients With Early HIV InfectionTerminatedNCT00016692Phase 1